A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance
CA 2392175 A1 · Owner: Mansson, Bengt · Inventors: Heinegard, Dick; Mansson, Bengt
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a conjugate of a collagen II-binding chondroadherin fragment and an arthritis-affecting pharmaceutical substance such as a , cytokine, a cytokine antagonist and/or a protease inhibitor. It has turned out that chondroadherin specifically interacts with collagen II thereby forming a complex. Release of cartilage extracellular matrix components such as , chondroadherin and collagen II is a symptom of arthitis. By providing a conjugate according to the present invention it is therefore possible to direct arthitis-affecting pharmaceutical substances directly to the pathogenic tissue. The inventive conjugate can be manufactured by chemical crosslinking. In case the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.